US4783484A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Particulate composition and use thereof as antimicrobial agent
Assignee: STS PARTICLES Inc
•
Filing: 1984-10-05
•
Granted: 1988-11-08
•
Expires: 2004-10-05
Abstract
Abstract A pharmaceutical composition combines a physiologically acceptable carrier with substantially uniformly sized particles of an organoiodide or organobromide which is solid at physiological tempertures, has a solubility in blood serum of less that one part per ten thousand, and has a mean particle diameter of from about 0.01 microns to about 4 microns. The method of the invention involves administering to a patient an effective amount of such particles.
Inventors
- 👤 Michael R. Violante
- 👤 Roy T. Steigbigel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 22:46
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61K31/245; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
74 words
A pharmaceutical composition suitable for treating a microbial infection of a patient which comprises a physiologically acceptable carrier in combination with an effective amount of substantially uniformly sized particles which are essentially comprised of an organoiodide or organobromide which is solid at physiological temperatures and has a solubility in blood serum of less than one part per ten thousand, and wherein the mean particle diameter is from about 0.01 microns to about 4 microns.
Claim 2
Dependent Claim
74 words
A pharmaceutical composition suitable for treating a microbial infection of a patient which comprises a physiologically acceptable carrier in combination with an effective amount of substantially uniformly sized particles which are essentially comprised of an organoiodide or organobromide which is solid at physiological temperatures and has a solubility in blood serum of less than one part per ten thousand, and wherein the mean particle diameter is from about 0.01 microns to about 4 microns.
Claim 3
Dependent Claim
17 words
The composition according to claim 1, wherein the particles are capable of enhancing intracellular killing of microorganisms.
Claim 4
Dependent Claim
28 words
The composition according to claim 1, wherein the iodide or bromide group can be cleaved through an intracellular metabolic pathway to produce a corresponding iodine or bromine anion.
Claim 5
Dependent Claim
22 words
The composition according to claim 1, wherein the particles are comprised of an aromatic or arylalkyl mono-, di-, or tri-iodide or bromide.
Claim 6
Dependent Claim
15 words
The composition according to claim 1, wherein the particles are comprised of iodipamide ethyl ester.
Claim 7
Dependent Claim
15 words
The composition according to claim 1, wherein the particles are comprised of iosefamate ethyl ester.
Claim 8
Dependent Claim
15 words
The composition according to claim 1, wherein the particles are comprised of iothalamate ethyl ester.
Claim 9
Dependent Claim
20 words
The composition according to claim 1, wherein the mean particle diameter is from about 1 micron to about 2 microns.
Claim 10
Dependent Claim
20 words
The composition according to claim 1, wherein the mean particle diameter is from about 0.01 microns to about 0.1 microns.
Claim 11
Dependent Claim
21 words
The composition according to claim 1, wherein the carrier is an aqueous solution capable of forming a suspension with the particles.
Claim 12
Independent Claim
81 words
A method for treating a microbial infection which comprises administering internally to a patient with an infection caused by an intracellular microorganism an effective amount of substantially uniformly sized particles which are essentially comprised of an organoiodide or organobromide which is solid at physiological temperatures and has a solubility in blood serum of less than one part per ten thousand, and wherein the mean particle diameter is from about 0.01 microns to about 4 microns, together with a physiologically acceptable carrier.
Claim 13
Independent Claim
81 words
A method for treating a microbial infection which comprises administering internally to a patient with an infection caused by an intracellular microorganism an effective amount of substantially uniformly sized particles which are essentially comprised of an organoiodide or organobromide which is solid at physiological temperatures and has a solubility in blood serum of less than one part per ten thousand, and wherein the mean particle diameter is from about 0.01 microns to about 4 microns, together with a physiologically acceptable carrier.
Claim 14
Dependent Claim
28 words
The method according to claim 11, wherein microorganisms are present in target cells of the patient and the administration of the particles enhances intracellular killing of the microorganisms.
Claim 15
Dependent Claim
12 words
The method according to claim 12, wherein the target cells are phagocytes.
Claim 16
Dependent Claim
30 words
The method according to claim 12, wherein the target cells are the phagocytic cells of the circulatory system, liver, spleen, lung, bone marrow, central nervous system, integument, or gastrointestinal tract.
Claim 17
Dependent Claim
16 words
The method according to claim 12, wherein the target cells are polymorphonuclear leukocytes or mononuclear phagocytes.
Claim 18
Dependent Claim
27 words
The method according to claim 11, wherein the iodide or bromide group is cleaved through an intracellular metabolic pathway to produce a corresponding iodine or bromine anion.
Claim 19
Dependent Claim
22 words
The method according to claim 11, wherein the particles are comprised of an aromatic or arylalkyl mono-, di-, or tri-iodide or bromide.
Claim 20
Dependent Claim
15 words
The method according to claim 11, wherein the particles are comprised of iodipamide ethyl ester.
Claim 21
Dependent Claim
35 words
The method according to claim 11, wherein the particles are comprised of iodipamide ethyl ester and the dose is from about 0.005 mg to about 400 mg of iodipamide ethyl ester per kilogram body weight.
Claim 22
Dependent Claim
15 words
The method according to claim 11, wherein the particles are comprised of iosefamate ethyl ester.
Claim 23
Dependent Claim
15 words
The method according to claim 11, wherein the particles are comprised of iothalamate ethyl ester.
Claim 24
Dependent Claim
20 words
The method according to claim 11, wherein the mean particle diameter is from about 1 micron to about 2 microns.
Claim 25
Dependent Claim
20 words
The method according to claim 11 wherein the mean particle diameter is from about 0.01 microns to about 0.1 microns.
Claim 26
Dependent Claim
15 words
The method according to claim 11, wherein the particles are administered as an aqueous suspension.
Claim 27
Dependent Claim
13 words
The method according to claim 11, wherein the route of administration is parenteral.
Claim 28
Dependent Claim
34 words
The method according to claim 11, wherein the dose is that amount of particles calculated to contain from about 0.003 mg to about 200 mg equivalent of iodide or bromide per kilogram body weight.
Claim 29
Dependent Claim
18 words
The method according to claim 11, wherein the infection is caused by a facultative or obligate intracellular parasite.
Claim 30
Dependent Claim
31 words
The method according to claim 11, wherein the infection is caused by a fungus, a yeast, a bacteria, a helminthes, a rickettsia, a chlamydia, a protozoa, a mycobacteria, or a virus.
Claim 31
Dependent Claim
39 words
The method according to claim 11, wherein the particle comprises iodipamide ethyl ester of a particle size of about 1 micron to about 2 microns, and the dose is about 0.05 mg iodipamide ethyl ester per kilogram body weight.
References Cited (Backward Citations)
US2776241A
Cited
US2919181A
Cited
GB867650A
Cited
US2861024A
Cited
US3489686A
Cited
US3761417A
Cited
US3723325A
Cited
US3753916A
Cited
US3761418A
Cited
US3580853A
Cited
US3663685A
Cited
US3875071A
Cited
US4059624A
Cited
US3919190A
Cited
US4009232A
Cited
US3892800A
Cited
US3957741A
Cited
US4005188A
Cited
US4180619A
Cited
US4105598A
Cited
US4406878A
Cited
US4234600A
Cited
US4395391A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-08 | 1992-05-09 | 1992-11-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-08 | 1996-05-09 | 1996-11-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-08 | 2000-05-09 | 2000-11-08 | $7700.00 | Window Closed / Lapsed |